New results from the Phase 3 ACHIEVE-1 trial show that Lilly’s investigational pill, orforglipron, significantly lowered blood sugar and body weight in adults with early type 2 diabetes. Taken once daily without food or water restrictions, orforglipron helped most participants reach target A1C levels and lose up to 16 pounds over 40 weeks.
The trial included 559 adults who were managing their diabetes with diet and exercise alone. At higher doses, orforglipron reduced A1C by up to 1.6 percentage points and body weight by nearly 8%. These results were published in The New England Journal of Medicine and presented at ADA 2025.
As an oral alternative to injectable GLP-1 medications, orforglipron may offer a more convenient option for people who prefer pills. Side effects were mainly mild-to-moderate stomach issues that occurred early in treatment. No severe low blood sugar events were reported.
Orforglipron is still in development and not yet approved. Lilly plans to seek regulatory approval for obesity treatment later in 2025 and for type 2 diabetes in 2026.
